Found: 140
Select item for more details and to access through your institution.
Prognostic impact of 1q abnormality on outcomes in patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone in a real-world clinical setting.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma.
- Published in:
- International Journal of Hematology, 2024, v. 120, n. 1, p. 91, doi. 10.1007/s12185-024-03770-8
- By:
- Publication type:
- Article
NK and T-lymphocyte Kinetics Predict Outcome in Myeloma Patients Treated With Elotuzumab, Lenalidomide Plus Dexamethasone.
- Published in:
- Cancer Diagnosis & Prognosis, 2024, v. 4, n. 2, p. 97, doi. 10.21873/cdp.10293
- By:
- Publication type:
- Article
Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long‐term outcomes in the Phase 3 IKEMA study.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 2, p. 1, doi. 10.1002/hon.3258
- By:
- Publication type:
- Article
Prognostic value of the second revision of the international staging system (R2‐ISS) in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 1, p. 1, doi. 10.1002/hon.3248
- By:
- Publication type:
- Article
Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 12, p. 3489, doi. 10.1007/s00277-023-05432-x
- By:
- Publication type:
- Article
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial.
- Published in:
- EJHaem, 2023, v. 4, n. 4, p. 995, doi. 10.1002/jha2.759
- By:
- Publication type:
- Article
Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 10, p. e360, doi. 10.1016/j.clml.2023.06.011
- By:
- Publication type:
- Article
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00797-8
- By:
- Publication type:
- Article
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 9, p. 2493, doi. 10.1007/s00277-023-05212-7
- By:
- Publication type:
- Article
Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Anti‐CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 442, doi. 10.1002/hon.3105
- By:
- Publication type:
- Article
Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatment.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 6, p. 1477, doi. 10.1007/s00277-023-05218-1
- By:
- Publication type:
- Article
Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan.
- Published in:
- PLoS ONE, 2023, v. 17, n. 5, p. 1, doi. 10.1371/journal.pone.0285947
- By:
- Publication type:
- Article
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00797-8
- By:
- Publication type:
- Article
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib‐dexamethasone versus physician's choice.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 5, p. 720, doi. 10.1002/ajh.26866
- By:
- Publication type:
- Article
Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma.
- Published in:
- International Journal of Hematology, 2023, v. 117, n. 5, p. 729, doi. 10.1007/s12185-023-03538-6
- By:
- Publication type:
- Article
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 4, p. 863, doi. 10.1007/s00277-023-05090-z
- By:
- Publication type:
- Article
Once Monthly Elotuzumab and Lenalidomide Plus Dexamethasone for Multiple Myeloma: A Multicenter Observation Study.
- Published in:
- Acta Haematologica, 2023, v. 146, n. 2, p. 125, doi. 10.1159/000528700
- By:
- Publication type:
- Article
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00797-8
- By:
- Publication type:
- Article
Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE‐1 (phase 2) Japanese cohort.
- Published in:
- Cancer Science, 2022, v. 113, n. 12, p. 4267, doi. 10.1111/cas.15556
- By:
- Publication type:
- Article
Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study.
- Published in:
- Japanese Journal of Clinical Oncology, 2022, v. 52, n. 12, p. 1446, doi. 10.1093/jjco/hyac137
- By:
- Publication type:
- Article
Lung-Cancer Risk in Mice after Exposure to Gamma Rays, Carbon Ions or Neutrons: Egfr Pathway Activation and Frequent Nuclear Abnormality.
- Published in:
- Radiation Research, 2022, v. 198, n. 5, p. 475, doi. 10.1667/RADE-21-00192.1
- By:
- Publication type:
- Article
Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.
- Published in:
- International Journal of Hematology, 2022, v. 116, n. 4, p. 553, doi. 10.1007/s12185-022-03378-w
- By:
- Publication type:
- Article
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e751, doi. 10.1016/j.clml.2022.04.005
- By:
- Publication type:
- Article
Health‐related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 6, p. 719, doi. 10.1002/ajh.26536
- By:
- Publication type:
- Article
Two‐year outcomes of tirabrutinib monotherapy in Waldenström's macroglobulinemia.
- Published in:
- Cancer Science, 2022, v. 113, n. 6, p. 2085, doi. 10.1111/cas.15344
- By:
- Publication type:
- Article
Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 1, p. 191, doi. 10.1007/s00432-021-03668-6
- By:
- Publication type:
- Article
Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry.
- Published in:
- Annals of Hematology, 2021, v. 100, n. 12, p. 2989, doi. 10.1007/s00277-021-04634-5
- By:
- Publication type:
- Article
Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 11, p. 785, doi. 10.1016/j.clml.2021.06.005
- By:
- Publication type:
- Article
P-193: Elotuzumab plus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S143, doi. 10.1016/S2152-2650(21)02320-X
- By:
- Publication type:
- Article
P-198: Isatuximab plus Carfilzomib and Dexamethasone in East Asian patients with relapsed Multiple Myeloma: IKEMA subgroup analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S146, doi. 10.1016/S2152-2650(21)02325-9
- By:
- Publication type:
- Article
P-208: Ongoing trials investigating in-class transition (iCT) from parenteral to oral proteasome inhibitor (PI)-based treatment with ixazomib in multiple myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S153, doi. 10.1016/S2152-2650(21)02335-1
- By:
- Publication type:
- Article
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 4, p. 784, doi. 10.1111/bjh.17541
- By:
- Publication type:
- Article
Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 1, p. 132, doi. 10.1111/bjh.17435
- By:
- Publication type:
- Article
Expression of activated integrin β7 in multiple myeloma patients.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma.
- Published in:
- Acta Haematologica, 2021, v. 144, n. 3, p. 264, doi. 10.1159/000508529
- By:
- Publication type:
- Article
Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients.
- Published in:
- Journal of Clinical Pharmacology, 2021, v. 61, n. 5, p. 614, doi. 10.1002/jcph.1771
- By:
- Publication type:
- Article
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 5, p. 869, doi. 10.1111/bjh.16980
- By:
- Publication type:
- Article
Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR.
- Published in:
- International Journal of Hematology, 2021, v. 113, n. 2, p. 219, doi. 10.1007/s12185-020-03013-6
- By:
- Publication type:
- Article
The Utility of the Energy Subtraction Method for Thoracic Spine Radiography in Clinical Practice: An Analysis of 25 Patients With Multiple Myeloma.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Statistical Optimisation of Phenol Degradation and Pathway Identification through Whole Genome Sequencing of the Cold-Adapted Antarctic Bacterium, Rhodococcus sp. Strain AQ5-07.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 24, p. 9363, doi. 10.3390/ijms21249363
- By:
- Publication type:
- Article
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study.
- Published in:
- Cancer Science, 2020, v. 111, n. 12, p. 4526, doi. 10.1111/cas.14657
- By:
- Publication type:
- Article
A multicenter, open‐label, phase II study of tirabrutinib (ONO/GS‐4059) in patients with Waldenström's macroglobulinemia.
- Published in:
- Cancer Science, 2020, v. 111, n. 9, p. 3327, doi. 10.1111/cas.14561
- By:
- Publication type:
- Article
Pomalidomide‐bortezomib‐dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM.
- Published in:
- Cancer Science, 2020, v. 111, n. 6, p. 2116, doi. 10.1111/cas.14415
- By:
- Publication type:
- Article
Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study.
- Published in:
- 2020
- By:
- Publication type:
- journal article